Digoxin Heart Failure

Digoxin is a cardiac glycoside derived from the foxglove plant Digitalis lanata that has been used in human and veterinary cardiology for decades to manage congestive heart failure and certain supraventricular tachyarrhythmias. In feline medicine, digoxin occupies a specialized but declining niche, used primarily in cases of dilated cardiomyopathy with systolic dysfunction and for rate control in cats with supraventricular tachycardia or atrial fibrillation. The drug's extremely narrow therapeutic index makes it one of the most challenging medications to use safely in cats, requiring precise dosing, regular serum concentration monitoring, and meticulous attention to the patient's renal function, electrolyte status, and concurrent medications. Despite these challenges, digoxin remains a valuable therapeutic option when other treatments prove insufficient or when its specific pharmacological profile is needed.

The use of digitalis compounds in medicine predates modern pharmacology by centuries, with William Withering's landmark 1785 publication describing the clinical effects of foxglove extract on dropsy, the historical term for fluid accumulation caused by heart failure. Modern pharmaceutical digoxin is a purified glycoside that provides consistent pharmacological activity compared to crude plant extracts. No veterinary-specific digoxin formulation exists for cats, and all feline use involves human-labeled products prescribed extra-label under the Animal Medicinal Drug Use Clarification Act. The available formulations include oral tablets in several strengths, a pediatric oral elixir that facilitates more precise feline dosing, and an injectable solution for intravenous administration in acute settings.

The clinical context for digoxin use in cats differs substantially from its application in dogs, where it is more commonly prescribed. Feline heart disease is dominated by hypertrophic cardiomyopathy, a condition characterized by thickened ventricular walls and diastolic dysfunction for which digoxin is generally not indicated and may be harmful. Dilated cardiomyopathy, the primary cardiac indication for digoxin's positive inotropic effects, is relatively uncommon in cats since the recognition that taurine deficiency was a major cause and the subsequent supplementation of commercial cat foods with adequate taurine levels. Nonetheless, cases of idiopathic dilated cardiomyopathy and end-stage myocardial failure from various etiologies do occur in cats, and digoxin may be considered as part of the therapeutic regimen for these patients.

The decision to prescribe digoxin to a cat reflects a careful weighing of potential benefits against substantial risks and typically occurs after consultation with or referral to a veterinary cardiologist. Advances in feline cardiac therapeutics have introduced alternative positive inotropic agents such as pimobendan, which has gained favor for many of the indications traditionally addressed by digoxin due to its wider safety margin and combined inotropic and vasodilatory properties. Nevertheless, digoxin's unique antiarrhythmic properties, particularly its ability to slow atrioventricular conduction and control ventricular response rates in atrial fibrillation and other supraventricular tachyarrhythmias, maintain its relevance in feline cardiology for specific patient populations.

The primary indication for digoxin in cats is the management of congestive heart failure associated with systolic myocardial dysfunction, most commonly dilated cardiomyopathy. In this condition, the ventricular myocardium loses its ability to contract effectively, leading to reduced cardiac output, compensatory neurohormonal activation, and the accumulation of fluid in the lungs, pleural space, or abdomen. Digoxin's positive inotropic effect strengthens myocardial contraction, modestly improving cardiac output and helping to alleviate the clinical signs of heart failure including dyspnea, lethargy, exercise intolerance, and fluid accumulation. However, digoxin is rarely used as monotherapy for heart failure in cats and is typically prescribed as one component of a multimodal treatment regimen that includes diuretics, angiotensin-converting enzyme inhibitors, and potentially other agents.

Supraventricular tachyarrhythmias represent the second major indication for digoxin in feline patients. Atrial fibrillation, while less common in cats than in dogs or horses, does occur particularly in cats with severe atrial enlargement secondary to cardiomyopathy. Digoxin slows conduction through the atrioventricular node, reducing the ventricular response rate and allowing more efficient ventricular filling during diastole. This rate-controlling effect improves hemodynamic function even without direct antiarrhythmic conversion to normal sinus rhythm. Other supraventricular tachycardias, including atrial flutter and certain reentrant tachycardias involving the atrioventricular node, may also respond to digoxin's effects on atrioventricular conduction. In these arrhythmic indications, digoxin may be used alone or in combination with other rate-controlling agents such as diltiazem or beta-blockers.

The neurohormonal modulatory effects of digoxin have gained recognition as a potentially important therapeutic mechanism beyond the traditional understanding of positive inotropy. Digoxin sensitizes baroreceptors and reduces sympathetic nervous system activation, effects that may be beneficial in the setting of heart failure where excessive sympathetic tone contributes to disease progression. These neurohormonal effects occur at lower serum concentrations than those required for maximal inotropic effect, supporting the contemporary practice of targeting lower serum digoxin levels than were historically considered therapeutic. In cats, the neurohormonal benefits are less well characterized than in human patients, but the theoretical advantages contribute to the rationale for low-dose digoxin therapy in selected feline heart failure cases.

Digoxin is specifically not indicated for, and may be harmful in, several common feline cardiac conditions. Hypertrophic cardiomyopathy, the most prevalent form of heart disease in cats, involves thickened ventricular walls with preserved or enhanced systolic function but impaired diastolic relaxation. In this context, increasing the force of myocardial contraction with digoxin could worsen dynamic left ventricular outflow tract obstruction and is not beneficial for the underlying diastolic dysfunction. Similarly, restrictive cardiomyopathy, characterized by impaired ventricular filling due to myocardial or endomyocardial fibrosis, does not benefit from positive inotropy. The exception arises when cats with these conditions develop concurrent supraventricular tachyarrhythmias that require rate control, in which case digoxin may be cautiously considered for its antiarrhythmic rather than inotropic properties.

Dosing digoxin in cats demands exceptional precision due to the drug's narrow therapeutic index and the relatively small body size of feline patients. The commonly recommended oral dose for cats is 0.005 to 0.01 milligrams per kilogram administered every 48 hours, though some references suggest dosing every 24 to 48 hours depending on the clinical indication, the individual patient's response, and serum drug level monitoring results. This dosing interval is notably longer than in dogs, reflecting the cat's slower clearance of digoxin and the species' heightened sensitivity to cardiac glycoside toxicity. The importance of individualizing the dose based on the patient's lean body weight cannot be overstated, as digoxin distributes primarily into lean tissue rather than adipose tissue, and dosing based on total body weight in obese cats can result in relative overdosing.

The oral elixir formulation of digoxin at 0.05 milligrams per milliliter is often preferred for feline dosing because it allows more precise measurement of the small doses required for cats compared to attempting to split or compound the smallest available tablet of 0.0625 milligrams. Using a calibrated oral syringe to measure the elixir dose ensures accuracy that is difficult to achieve with tablet administration. However, the elixir contains excipients including alcohol and propylene glycol that may affect palatability and, in the case of propylene glycol, raise concerns about potential toxicity with chronic use in cats, as this species is sensitive to propylene glycol-induced Heinz body anemia. Veterinarians weigh the benefits of precise dosing against these excipient concerns when selecting the formulation for each patient.

For cats requiring inotropic or rate-controlling effects more urgently than oral dosing allows, intravenous digoxin may be administered in a hospital setting under continuous electrocardiographic monitoring. Intravenous loading protocols, when used, employ lower total loading doses than those used in dogs and are administered in divided increments over several hours rather than as a single bolus, as rapid intravenous administration greatly increases the risk of fatal arrhythmias. Many veterinary cardiologists prefer to avoid intravenous loading entirely in cats, opting instead for oral administration and accepting the longer time required to achieve steady-state therapeutic levels, which typically occurs after five to seven half-lives.

The every-other-day dosing regimen commonly used in cats simplifies the administration schedule but requires owner compliance with an alternating-day routine that some may find challenging. Owners should be instructed to administer digoxin at consistent times relative to meals, as food can alter absorption kinetics, and to establish a reliable tracking method such as a calendar notation or medication tracking app to avoid missed or doubled doses. If a dose is missed, it should be given as soon as remembered on the appropriate dosing day, but if it is not discovered until the next dosing day, the missed dose should be skipped entirely and the regular alternating schedule resumed. The drug should never be doubled up to compensate for a missed dose.

Digoxin should be administered with caution and under strict veterinary supervision when initiating therapy or adjusting doses. The initial dosing period is particularly critical because steady-state drug levels are not reached for approximately five to seven days after starting therapy or changing the dose, and early signs of toxicity may emerge during this equilibration period. Veterinarians typically schedule serum digoxin level measurement seven to ten days after initiating therapy, timed to coincide with the predicted steady-state period. Dose adjustments based on these levels, clinical response, and any emerging signs of toxicity guide the ongoing management of the medication.

Digoxin's primary mechanism of action involves inhibition of the sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) enzyme located in the cell membranes of cardiac myocytes. This membrane-bound pump normally maintains the electrochemical gradient by transporting three sodium ions out of the cell and two potassium ions into the cell with each catalytic cycle, consuming one molecule of adenosine triphosphate in the process. When digoxin binds to and partially inhibits this pump, intracellular sodium concentration rises. The increased intracellular sodium reduces the driving force for the sodium-calcium exchanger (NCX), which normally uses the inward sodium gradient to extrude calcium from the cell. With less calcium being pumped out, intracellular calcium concentrations increase, and this additional calcium is taken up by the sarcoplasmic reticulum and released during subsequent contractions, resulting in stronger myocardial contraction. This is the basis of digoxin's positive inotropic effect.

The antiarrhythmic properties of digoxin, particularly its effects on atrioventricular conduction, involve both direct and indirect mechanisms that work in concert. The direct electrophysiological effects of digoxin on the atrioventricular node include shortening of the action potential duration and slight depression of conduction velocity within the nodal tissue. More importantly, digoxin enhances vagal (parasympathetic) tone to the heart through both central and peripheral mechanisms, increasing acetylcholine release at vagal nerve terminals innervating the sinoatrial and atrioventricular nodes. This enhanced vagal activity slows the heart rate, prolongs the refractory period of the atrioventricular node, and reduces conduction velocity through the node, collectively decreasing the number of supraventricular impulses transmitted to the ventricles during atrial fibrillation or other supraventricular tachyarrhythmias.

The neurohormonal modulation produced by digoxin contributes therapeutic benefits that are increasingly recognized as important in heart failure management. Digoxin restores baroreceptor sensitivity that is blunted in heart failure, which in turn reduces excessive sympathetic nervous system activation and decreases circulating levels of catecholamines and renin. Reduced sympathetic tone lowers peripheral vascular resistance, decreases myocardial oxygen demand, and attenuates the deleterious remodeling effects of chronic adrenergic stimulation on the failing myocardium. Additionally, digoxin may reduce circulating levels of aldosterone and vasopressin, hormones that contribute to sodium and water retention in heart failure. These neurohormonal effects have been demonstrated at serum digoxin concentrations lower than those required for maximal inotropic effect, supporting the modern practice of targeting relatively low therapeutic levels.

The pharmacokinetics of digoxin in cats differ from those in dogs and influence dosing strategy and monitoring protocols. Oral bioavailability of digoxin tablets in cats is reported at approximately 60 to 80 percent, while the elixir formulation may provide slightly higher and more consistent absorption. Digoxin distributes widely into tissues, with a volume of distribution of approximately 10 to 12 liters per kilogram in cats, reflecting extensive tissue binding. The drug binds preferentially to skeletal muscle and myocardium, with relatively low plasma protein binding of approximately 20 to 30 percent. Elimination occurs through both renal excretion of unchanged drug and hepatic metabolism, with the kidney being the predominant route. The elimination half-life in cats is approximately 33 to 58 hours, significantly longer than in dogs, which is the pharmacokinetic basis for the extended dosing interval recommended for feline patients.

Digoxin toxicity is the foremost clinical concern associated with this medication in cats, and the narrow margin between therapeutic and toxic serum concentrations makes toxicity a constant risk throughout the course of treatment. The therapeutic serum digoxin concentration range for cats is generally cited as 0.8 to 2.0 nanograms per milliliter, though contemporary evidence from human cardiology suggests that targeting the lower end of this range, between 0.5 and 1.0 nanograms per milliliter, may provide optimal therapeutic benefit with reduced toxicity risk. Toxicity can occur at serum levels within or only slightly above the traditional therapeutic range, particularly in cats with electrolyte abnormalities, renal insufficiency, or concurrent medications that alter digoxin pharmacokinetics. This narrow safety window underscores the absolute necessity of regular serum level monitoring.

Gastrointestinal signs are frequently the earliest manifestation of digoxin toxicity in cats and serve as important warning signals. Anorexia is often the first abnormality noted by owners and may precede other signs of toxicity by hours to days. Vomiting and diarrhea may follow, and the combination of decreased food intake and gastrointestinal fluid losses can lead to dehydration and electrolyte derangements that further potentiate toxicity. Nausea without overt vomiting may be recognized as excessive salivation, lip licking, or reluctance to approach the food bowl. Because anorexia and gastrointestinal upset are nonspecific symptoms that can occur with many feline conditions, including the heart disease being treated, clinical judgment is required to distinguish between disease progression and drug toxicity, with serum digoxin level measurement providing definitive guidance.

Cardiac toxicity represents the most dangerous manifestation of digoxin poisoning and can produce virtually any type of arrhythmia, making the cardiac glycoside paradoxically both an antiarrhythmic and a proarrhythmic agent depending on the dose and clinical context. The arrhythmias most characteristic of digoxin toxicity include ventricular premature complexes, ventricular bigeminy, ventricular tachycardia, accelerated junctional rhythms, paroxysmal atrial tachycardia with atrioventricular block, and high-degree atrioventricular block. The combination of enhanced automaticity in atrial and ventricular tissue with depressed conduction through the atrioventricular node is the electrophysiological hallmark of digoxin toxicity and produces characteristic patterns on electrocardiographic recording. Fatal ventricular fibrillation can occur in severe toxicity, making recognition and management of digoxin-induced arrhythmias a critical skill for veterinary practitioners managing digitalized cats.

Neurological manifestations of digoxin toxicity in cats may include depression, disorientation, and rarely, visual disturbances that are difficult to definitively diagnose in veterinary patients but are well documented in human toxicology. In humans, disturbances in color vision, particularly xanthopsia (yellow-tinted vision), are classic symptoms of digitalis toxicity, and while these cannot be directly assessed in cats, behavioral changes suggesting visual abnormalities should raise suspicion for toxicity. Generalized weakness and lethargy may reflect both the direct neurological effects of excessive digoxin and the hemodynamic consequences of drug-induced arrhythmias.

Hypokalemia is the single most important predisposing factor for digoxin toxicity and deserves particular emphasis in the feline clinical context. Digoxin and potassium compete for binding sites on the Na+/K+-ATPase, and when extracellular potassium is low, digoxin binding increases, intensifying its effects even when serum drug levels remain within the traditional therapeutic range. Cats receiving concurrent diuretic therapy, particularly loop diuretics such as furosemide that promote potassium excretion, are at heightened risk for hypokalemia-potentiated digoxin toxicity. This interaction is especially relevant because heart failure patients receiving digoxin are almost invariably receiving concurrent diuretic therapy as well. Regular monitoring of serum potassium and supplementation as needed to maintain normokalemia is essential in all cats receiving digoxin.

Digoxin participates in an extensive array of clinically significant drug interactions that can alter its serum concentration, modify its pharmacological effects, or predispose to toxicity. Given that cats with heart failure typically receive multiple concurrent medications, awareness of these interactions is essential for safe prescribing. Furosemide, the loop diuretic that is a cornerstone of heart failure management, interacts with digoxin primarily through its potassium-depleting effect, as discussed in the toxicity section, and this interaction is virtually unavoidable in clinical practice. Management involves regular potassium monitoring and supplementation, potassium-sparing dietary considerations, and vigilance for early signs of toxicity. Spironolactone, an aldosterone antagonist sometimes used in heart failure, has a potassium-sparing effect that is beneficial in this context but can also reduce renal digoxin clearance, potentially increasing serum levels.

Calcium channel blockers, particularly diltiazem, are frequently used alongside digoxin in cats with supraventricular tachyarrhythmias or hypertrophic cardiomyopathy. Diltiazem can increase serum digoxin concentrations by reducing renal and non-renal clearance, necessitating digoxin dose reduction and closer monitoring when these drugs are combined. The additive negative chronotropic effects of digoxin and diltiazem on the atrioventricular node can be therapeutically advantageous for rate control in atrial fibrillation but also increase the risk of excessive bradycardia and atrioventricular block. Similarly, beta-adrenergic blockers such as atenolol, used in some feline cardiac conditions, have additive effects on heart rate and atrioventricular conduction when combined with digoxin, requiring careful dose titration and electrocardiographic monitoring.

Antacids, metoclopramide, and other gastrointestinal medications can alter digoxin absorption from the gastrointestinal tract. Antacids and kaolin-pectin preparations may bind digoxin in the gut lumen and reduce its bioavailability if administered concurrently, while metoclopramide increases gastrointestinal motility and may reduce the time available for digoxin absorption. These interactions are managed by separating the administration times of digoxin and the interacting gastrointestinal medication by at least two hours. Conversely, drugs that slow gastrointestinal motility may increase digoxin absorption and potentially raise serum levels above the intended range.

Certain antibiotics commonly used in feline medicine can interact with digoxin through various mechanisms. Erythromycin and other macrolide antibiotics can increase serum digoxin levels, potentially through inhibition of P-glycoprotein-mediated intestinal and renal digoxin efflux. Tetracycline antibiotics may increase digoxin bioavailability in some patients by altering gastrointestinal flora that normally inactivate a portion of orally administered digoxin. When antibiotics known to interact with digoxin are prescribed to a cat already receiving the cardiac glycoside, additional serum level monitoring and dose adjustment may be necessary. Benazepril and enalapril, angiotensin-converting enzyme inhibitors used in feline heart failure management, have minimal direct pharmacokinetic interaction with digoxin but may affect renal function and potassium balance in ways that indirectly influence digoxin activity and clearance.

Digoxin is contraindicated in cats with hypertrophic obstructive cardiomyopathy where dynamic left ventricular outflow tract obstruction is present, as the positive inotropic effect can worsen the obstruction and precipitate hemodynamic collapse. The increased force of ventricular contraction narrows the outflow tract further, increasing the pressure gradient and potentially triggering systolic anterior motion of the mitral valve with acute clinical deterioration. This contraindication is particularly important in feline medicine because hypertrophic cardiomyopathy is by far the most common form of heart disease in cats, and clinicians must confidently distinguish it from the much less common dilated cardiomyopathy before considering digoxin therapy. Echocardiographic evaluation by a veterinary cardiologist or experienced practitioner is essential for establishing this distinction.

Ventricular tachycardia and ventricular fibrillation are absolute contraindications to digoxin administration, as the drug's proarrhythmic properties at toxic levels target the same ventricular tissues and could worsen these life-threatening rhythms. Similarly, second-degree or higher atrioventricular block in the absence of atrial tachyarrhythmia should preclude digoxin use because the drug's vagotonic effects and direct depression of atrioventricular conduction could advance the degree of block and cause hemodynamically significant bradycardia. Accessory pathway-mediated tachycardias, including Wolff-Parkinson-White syndrome, represent another contraindication because digoxin can enhance conduction through the accessory pathway while slowing atrioventricular nodal conduction, potentially facilitating dangerously rapid ventricular rates during atrial fibrillation.

Renal insufficiency significantly alters digoxin pharmacokinetics and requires dose modification. Because renal excretion is the primary elimination pathway for digoxin, reduced glomerular filtration rate leads to drug accumulation and increased risk of toxicity at standard doses. Chronic kidney disease is common in older cats, the same population most likely to develop cardiac conditions that might warrant digoxin use, making this interaction clinically relevant and frequently encountered. Dose reduction, typically by 50 percent or more, and increased monitoring frequency are necessary in cats with compromised renal function. Serial assessment of renal parameters alongside serum digoxin levels helps guide dosing in these patients.

Electrolyte disturbances beyond hypokalemia also influence digoxin safety and represent important precautions. Hypercalcemia potentiates digoxin's effects on the myocardium and increases the risk of toxicity, as calcium and digoxin have synergistic effects on intracellular calcium loading. Hypomagnesemia, like hypokalemia, predisposes to digoxin-induced arrhythmias and should be corrected before and maintained during digoxin therapy. Thyroid status affects digoxin sensitivity, with hypothyroid patients showing increased sensitivity to digoxin and hyperthyroid patients demonstrating relative resistance. Hyperthyroidism is common in older cats and may complicate the management of concurrent cardiac disease being treated with digoxin, as correction of hyperthyroidism can unmask or potentiate digoxin effects that were previously buffered by the hyperthyroid state.

Pregnancy represents a precaution for digoxin use in cats, as the drug crosses the placental barrier and is present in fetal tissues. While digoxin is classified as relatively low risk during pregnancy in human medicine and has been used to treat fetal arrhythmias in utero, the risks and benefits in pregnant cats have not been systematically evaluated. In breeding queens with cardiac conditions requiring digoxin, the necessity of treatment for maternal survival must be balanced against potential fetal effects, and the decision should involve specialized veterinary consultation.

Serum digoxin concentration monitoring is not merely recommended but essentially mandatory for the safe management of digoxin therapy in cats. The narrow therapeutic index of digoxin, the variability in absorption and clearance among individual patients, the influence of concurrent medications and changing renal function on drug levels, and the difficulty of clinically distinguishing early toxicity from disease progression all make serum level measurement an indispensable tool. The target therapeutic range for cats is generally cited as 0.8 to 2.0 nanograms per milliliter, though accumulating evidence from human cardiology increasingly supports targeting the lower end of this range, between 0.5 and 1.0 nanograms per milliliter, where neurohormonal benefits are preserved with substantially reduced toxicity risk.

The timing of blood sample collection relative to dosing is critical for the accurate interpretation of serum digoxin results. Blood should be drawn at least six to eight hours after the most recent oral dose to allow completion of the distribution phase, during which serum levels are transiently elevated and do not accurately reflect tissue concentrations. Many veterinary references recommend collecting serum samples eight to ten hours post-dose in cats. Given that cats on every-other-day dosing regimens present unique sampling considerations, some practitioners prefer to measure trough levels immediately before the next scheduled dose, which provides the most conservative estimate of the drug's tissue equilibrium concentration. Regardless of the specific timing chosen, consistency between serial measurements is essential for meaningful trend monitoring.

The initial serum digoxin level should be measured approximately seven to ten days after starting therapy, a timeframe that corresponds to the expected achievement of steady-state concentrations based on the feline elimination half-life. If the level is within the target range and the patient shows appropriate clinical response without signs of toxicity, monitoring may be performed at two to four week intervals initially, with extension to monthly or bimonthly intervals once the patient is stabilized. Any change in digoxin dose, addition or discontinuation of an interacting medication, change in renal function, development of new symptoms, or clinical deterioration should trigger repeat level measurement regardless of the routine monitoring schedule.

Interpretation of serum digoxin levels requires clinical context and should never be reduced to a simple comparison with a reference range. A serum level within the traditional therapeutic range does not guarantee the absence of toxicity, particularly in patients with hypokalemia, hypercalcemia, hypomagnesemia, or concurrent use of drugs that potentiate digoxin's cardiac effects. Conversely, a level slightly below the traditional range may provide adequate therapeutic benefit with lower toxicity risk, consistent with the contemporary low-dose approach. Correlation between the measured level, the clinical response, electrocardiographic findings, and the patient's overall status informs the decision about whether to maintain, increase, or decrease the dose.

Owner education about the significance and logistics of therapeutic drug monitoring contributes materially to patient safety. Cat owners should understand that digoxin monitoring requires blood tests at specific times relative to dosing and that these tests are not optional luxuries but essential safety measures. The cost and scheduling logistics of regular monitoring should be discussed before initiating therapy so that owners can make informed commitments to the required follow-up. Owners should also be instructed to report any changes in appetite, gastrointestinal function, activity level, or breathing pattern between monitoring visits, as these clinical observations complement laboratory data in the early detection of toxicity or therapeutic failure.

Acute digoxin overdose in cats requires immediate and aggressive emergency management, as the drug's cardiac effects can rapidly produce fatal arrhythmias. Ingestion of human-strength digoxin tablets by a cat can deliver massively excessive doses relative to the feline therapeutic range. A single 0.25 milligram tablet represents the total daily dose for a large cat and far exceeds what would be appropriate for most feline patients, while ingestion of multiple tablets or higher-strength formulations can quickly produce lethal serum concentrations. The narrow margin between therapeutic and toxic effects means that even modest overdoses relative to the prescribed amount can result in serious clinical consequences.

The clinical presentation of acute digoxin overdose typically involves the rapid development of life-threatening cardiac arrhythmias, which may include any combination of atrioventricular block, ventricular premature complexes, ventricular tachycardia, ventricular fibrillation, and asystole. Severe hyperkalemia frequently accompanies acute massive overdose due to inhibition of Na+/K+-ATPase throughout the body, causing potassium to shift from the intracellular to the extracellular compartment. The combination of direct cardiac toxicity and severe hyperkalemia creates a particularly dangerous hemodynamic situation. Gastrointestinal signs including profuse vomiting may occur early and can actually be beneficial by reducing further drug absorption, though they also risk aspiration in obtunded patients.

Decontamination measures for recent ingestion include induction of emesis in alert, stable cats within one to two hours of ingestion, followed by administration of activated charcoal. Multiple-dose activated charcoal is recommended for significant digoxin ingestions because the drug undergoes enterohepatic recirculation, and repeated charcoal doses can bind drug that re-enters the gastrointestinal tract via biliary excretion, reducing the total body burden more rapidly. Whole bowel irrigation may be considered for ingestion of sustained-release formulations, though these formulations are not commonly available in current markets.

In human medicine, digoxin-specific antibody fragments (Digibind or DigiFab) represent the definitive antidote for severe digoxin toxicity, binding free digoxin molecules and rendering them pharmacologically inactive. These antibody fragments have been used successfully in veterinary patients, including cats, though their availability in veterinary emergency settings is limited and their cost is substantial. When available, digoxin-specific antibody fragments can produce dramatic reversal of both cardiac and non-cardiac manifestations of digoxin toxicity. The dose is calculated based on the estimated body burden of digoxin, and the clinical response is typically rapid. Veterinary emergency facilities treating digoxin-poisoned cats should investigate the availability of these antidotal products through regional poison control centers or human hospital pharmacies.

Supportive management of digoxin toxicity focuses on cardiovascular stabilization and correction of electrolyte abnormalities. Atropine may be used to manage symptomatic bradycardia and atrioventricular block, though its effectiveness may be limited in severe toxicity. Lidocaine is the antiarrhythmic of choice for digoxin-induced ventricular tachyarrhythmias, while phenytoin has also been used for this indication due to its ability to suppress enhanced automaticity without further depressing atrioventricular conduction. Aggressive correction of hyperkalemia with intravenous calcium gluconate, sodium bicarbonate, and insulin-dextrose may be life-saving in acute massive overdose. Continuous electrocardiographic monitoring is mandatory throughout the treatment period, and the prolonged elimination half-life of digoxin in cats means that monitoring and supportive care may be required for an extended period after the initial stabilization.